Return to Main Site 617-919-3019
401 Park Drive, 7th Floor East, Boston, MA 02215

TIDO Technology Search



Invention Type

Diagnostic/Prognostic
Information Technology/Software
Medical Device
Other
Research Tool
Therapeutics

Research Area

Allergy/Respiratory/Pulmonary Disease
Anesthesia
Cardiovascular/Cardiology
Degenerative Disease
Dermatology
Endocrinology
Gastrointestinal/Nutrition
Genetic Disease
Health Care Management
Immunology
Infectious Disease
Inflammation
Internal Medicine
Metabolic Disease
Musculoskeletal
Neonatology/Pediatric
Neurology/Neuroscience
Oncology/Hematology
Ophthalmology
Otolaryngology/Audiology
Pain
Pathology
Personalized Medicine
Psychiatric Disease
Radiology
Regenerative Medicine
Reproduction/Ob-Gyn
Stem Cell
Surgery/Wound Healing
Urology
CMCC 2805

Novel adjuvant supplement to boost vaccine efficacy

Inventors: Jonathan Kagan

Invention Types: Therapeutics

Research Areas: Immunology

Keywords: Assay

For More Information Contact:  Meyer, Abbie

 

Invention Description:

Modern day vaccines that use highly purified antigens are safer and well tolerated at the expense of significantly reduced immunogenicity when compared to old fashion live or killed whole pathogen vaccines. These vaccines are often supplemented with adjuvants to produce optimal immune response. Current adjuvants in the market (i.e., alum) are effective inducing humoral immune response by boosting antibody production but are less efficient at modulating innate immunity necessary to eradicate infections. ||

Dr. Kagan’s group identified and characterized a novel fatty adjuvant oxPAPC that is able to promote dendritic cell survival and the release of cytokine interleukin-1β (IL-1β) that triggers memory T-cell production. When oxPAPC is administered subcutaneously to mice, the dendritic cells enter a “hyperactivation state” and show a 5-fold increase in adaptive immunity. Another of their key findings is that oxPAPC acts via caspase-11 to promote hyperactivation of dendritic cells.


Notably, oxPAPC is unique among known adjuvants in its ability to stimulate dendritic cells specifically, not macrophages. Both of these cell types are stimulated by all other adjuvants on the market, with macrophages being the major source of painful inflammation during vaccination, oxPAPC may facilitate the development of vaccines with less reactogenicity.

Applications:

An adjuvant that activates both innate and adaptive immune systems, and increase immunogenic response to a wide range of vaccine types.

Competitive Advantages:

• OxPAPC selectively targets dendritic cells to induce strong memory T-cell activation with a long lasting effect that is not efficiently elicited by normal activated dendritic cells.

• May be administered nasally or orally.

• Reduced likeliness of painful inflammation during vaccination

Business Opportunity:

Licensing agreement or sponsored research.

Key Publications: Zanoni et al., An endogenous caspase-11 ligand elicits interleukin-1 release from living dendritic cells. Science 2016 Apr 21 pii: aaf3036. [Epub ahead of print]

IPStatus: Pat. Pend.